<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615066</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-389-2025</org_study_id>
    <nct_id>NCT03615066</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Antiviral Activity of Selgantolimod in Viremic Adults With Chronic Hepatitis B Who Are Not Currently on Treatment</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability, antiviral
      activity of multiple oral doses of selgantolimod (formerly GS-9688) in chronic hepatitis B
      (CHB) adults who are viremic and currently not being treated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">December 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis Surface Antigen (qHBsAg) from Baseline at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum qHBsAg (log10 IU/mL) From Baseline at Week 4</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum qHBsAg (log10 IU/mL) From Baseline at Week 8</measure>
    <time_frame>Baseline; Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum qHBsAg (log10 IU/mL) From Baseline at Week 12</measure>
    <time_frame>Baseline; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum qHBsAg (log10 IU/mL) From Baseline at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum qHBsAg (log10 IU/mL) From Baseline at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBV DNA &lt; Lower Limit of Quantitation (LLOQ) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBV DNA &lt; LLOQ at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBV DNA &lt; LLOQ at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBsAg Loss at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBsAg Loss at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with HBsAg Loss at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with the Composite Endpoint of HBeAg Loss and Seroconversion at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with the Composite Endpoint of HBeAg Loss and Seroconversion at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with the Composite Endpoint of HBeAg Loss and Seroconversion at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Virologic breakthrough is defined as having two consecutive visits of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 69 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Drug Resistance Mutations</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Placebo (Cohort 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HBeAg-positive participants will receive tenofovir alafenamide (TAF) and selgantolimod placebo for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/Early Discontinuation (ED). The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the Treatment Free Follow-Up (TFFU) phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-positive participants will receive TAF and selgantolimod 1.5 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selgantolimod 3 mg (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-positive participants will receive TAF and selgantolimod 3 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohort 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HBeAg-negative participants will receive TAF and selgantolimod placebo for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative participants will receive TAF and selgantolimod 1.5 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selgantolimod 3 mg (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative participants will receive TAF and selgantolimod 3 mg for 24 doses. After the 24th dose, participants will continue receiving TAF until Week 48/ED. The total study duration for each participant will be 48 weeks with up to an additional 48 weeks if continued into the TFFU phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selgantolimod Placebo</intervention_name>
    <description>Tablet(s) administered orally every 7 days for 24 doses in fasted state</description>
    <arm_group_label>Placebo (Cohort 1)</arm_group_label>
    <arm_group_label>Placebo (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selgantolimod</intervention_name>
    <description>Tablet(s) administered orally every 7 days for 24 doses in fasted state</description>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 2)</arm_group_label>
    <arm_group_label>Selgantolimod 3 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Selgantolimod 3 mg (Cohort 2)</arm_group_label>
    <other_name>GS-9688</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>25 mg tablet(s) administered orally once daily for 48 weeks with food</description>
    <arm_group_label>Placebo (Cohort 1)</arm_group_label>
    <arm_group_label>Placebo (Cohort 2)</arm_group_label>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Selgantolimod 1.5 mg (Cohort 2)</arm_group_label>
    <arm_group_label>Selgantolimod 3 mg (Cohort 1)</arm_group_label>
    <arm_group_label>Selgantolimod 3 mg (Cohort 2)</arm_group_label>
    <other_name>Vemlidy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form, which
             must be obtained prior to initiation of study procedures.

          -  Adult male and non-pregnant, non-lactating females

          -  Documented evidence of chronic HBV infection with detectable HBsAg levels

          -  Screening HBV DNA ≥ 2000 IU/mL.

          -  Screening electrocardiogram (ECG) without clinically significant abnormalities

        Key Exclusion Criteria:

          -  Extensive bridging fibrosis or cirrhosis

          -  Received a commercially available HBV OAV treatment(s) within the 3 months prior to
             screening.

          -  Received prolonged therapy with immunomodulators or biologics within 3 months of
             screening

          -  Individuals meeting any of the following laboratory parameters at screening:

               -  Alanine aminotransferase &gt; 5 x upper limit of normal (ULN)

               -  International normalized ratio &gt; ULN unless the individual is stable on an
                  anticoagulant regimen

               -  Albumin &lt; 3.5 g/dL

               -  Direct bilirubin &gt;1.5x ULN

               -  Platelet Count &lt; 100,000/µL

               -  Estimated creatinine clearance &lt; 60 mL/min (using the Cockcroft-Gault method)

          -  Co-infection with human immunodeficiency virus (HIV), hepatitis C virus or hepatitis D
             virus

          -  Prior history of hepatocellular carcinoma or screening alpha-fetoprotein ≥ 50 ng/mL
             without imaging

          -  Diagnosis of autoimmune disease poorly controlled diabetes mellitus, significant
             psychiatric illness, severe chronic obstructive pulmonary disease, hemoglobinopathy,
             retinal disease, or are immunosuppressed.

          -  Chronic liver disease of a non-HBV etiology except for non-alcoholic fatty liver
             disease.

          -  Received solid organ or bone marrow transplant.

          -  Use of another investigational agent within 90 days of screening, unless allowed by
             the sponsor.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary Liver Unit - Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital, Toronto Centre for Liver Disease</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

